CME at Risk Dear Editor: Good issue! A couple of comments regarding your July/August editorial [“CME at Risk”]: Yes, at the moment, CME is at risk. Funding for CME is shifting perceptibly to promotional education, because, in pharmaceutical companies that have recently separated medical education from promotion, product managers are reluctant to “lose control” by assigning dollars to programs managed through scientific affairs or a similar department. You are optimistic when you suggest ...

Register for Complete Access (Valid Email Required)

By registering on MeetingsNet now, you'll not only unlock the Letters to the Editor, you'll also gain access to exclusive premium content.

Already registered? here.